News
McGill University joins Phase II efficacy trial
McGill University Health Centre in Montreal is one of the leading academic health centres in the world. They will be participating in…
Patient 5 still cancer-free 18 months after single treatment
Patient five has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540…
Phase II trial approved for TLD-1433
Research Ethics Board approval has been obtained to move TLD-1433 to a Phase II trial for non-muscle invasive bladder cancer, using the…
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Three patients (patients four, five and six) were enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with patient 4 successfully achieving…
Excellent patient health update
Patients five and six remain cancer-free after one year and nine months, respectively, of their single treatment with TLD-1433! In other news,…
Patient 6: Cancer-free at six months
Following the success of Patient 5, Patient 6 has now also demonstrated no recurrence of bladder cancer at the 180 day clinical…
Patient 5: Cancer-free at six months
Patient 5 tolerated the single-dose treatment well, and has demonstrated no tumor recurrence or presence of disease at the 180 day clinical…
Phase Ib trial successfully completed
Based on the encouraging results of the first patients in the trial, the Medical and Scientific Advisory Board (“MSAB”) unanimously recommended the…
AGM videos online
Theralase has released three videos that were presented at its annual meeting. They cover the successful completion of the Phase Ib trial,…
More great news from the clinical trial
Very encouraging news from the clinic! Patient Five shows no clinical evidence or presence of NMIBC (non muscle invasive bladder cancer) at…
